Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 11/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | USP2 | O75604 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | RAF1 | P04049 | 2/20 | 0.52 |
| ▸ | BRAF | P15056 | 2/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.50 |
| ▸ | CLK1 | P49759 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183411 | 0.90 | PIK3CD (0.58) | CLK4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL182389 | 0.90 | PIK3CD (0.58) | CLK4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL182735 | 0.84 | PIK3CD (0.64) | CLK4RAF1BRAFKITPIK3CD | |
| SCHEMBL183019 | 0.84 | PIK3CD (0.64) | CLK4RAF1BRAFKITPIK3CD | |
| SCHEMBL182570 | 0.83 | PIK3CD (0.58) | CLK4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL182854 | 0.83 | PIK3CD (0.58) | CLK4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL182860 | 0.79 | KIT (0.53) | RAF1BRAFKITPIK3CDPIK3CA | |
| SCHEMBL6182448 | 0.77 | KIT (0.78) | KITPIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL3520125 | 0.76 | CLK4 (0.62) | CLK4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL182771 | 0.76 | PIK3CD (0.73) | CLK4RAF1BRAFKITPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | claimed |
| EP-2049502-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | claimed |
| WO-2008012326-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | claimed |
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIK3CA | CLK4 586/4885CYP1A2 622/4885CYP3A4 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.